This atypical deal structure will see Gilead collaborate with Galapagos to develop gamgertamig for the treatment of B-cell mediated autoimmune diseases.
Autonomous biopharma lab developers say the future of R&D will be defined by human-AI collaboration.
Gilead acquired Arcellx to gain the development and marketing rights to anito-cel, for which GlobalData forecasts sales of $658m by 2032 across 8MM.
The somatic genomics approach analyses naturally accumulated genetic mutations within individual patient tissue.
The partnership will see Viz.ai develop an AI Care Pathway for cardiac amyloidosis.
The partnership aims to speed up early-phase clinical development and provide new therapies to patients.
